CR7163A - Formulaciones autoemulsionantes de inhibnidores de la proteina de transferencia de colesteril ester - Google Patents

Formulaciones autoemulsionantes de inhibnidores de la proteina de transferencia de colesteril ester

Info

Publication number
CR7163A
CR7163A CR7163A CR7163A CR7163A CR 7163 A CR7163 A CR 7163A CR 7163 A CR7163 A CR 7163A CR 7163 A CR7163 A CR 7163A CR 7163 A CR7163 A CR 7163A
Authority
CR
Costa Rica
Prior art keywords
self
cholesterile
emulsioning
formulations
ester
Prior art date
Application number
CR7163A
Other languages
English (en)
Inventor
Jon Gumlowski Michael
Balasaheb Murdande Sharad
Ellis Perlam Michael
Lombardo Franco
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CR7163A publication Critical patent/CR7163A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Inhibidores de CETP que tienen mejor solubilidad y biodisponibilidad en un vehiculo lipofilo que comprende un aceite digerible, un disolvente lipofilo o un tensioactivo. Tales composiciones preferidas son autoemulsionantes o automicroemulsionantes y comprenden un inhibidor de CETP, un codisolvente, un tensioactivo que tiene un HLB de 1 a 8, un tensioactivo que tiene un HLB de 8 a 20, y opcionalmente, un aceite digerible.
CR7163A 2001-06-21 2003-11-24 Formulaciones autoemulsionantes de inhibnidores de la proteina de transferencia de colesteril ester CR7163A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30002801P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
CR7163A true CR7163A (es) 2004-02-23

Family

ID=23157363

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7163A CR7163A (es) 2001-06-21 2003-11-24 Formulaciones autoemulsionantes de inhibnidores de la proteina de transferencia de colesteril ester

Country Status (33)

Country Link
US (2) US6962931B2 (es)
EP (1) EP1453544A2 (es)
JP (1) JP2005500314A (es)
KR (1) KR20040015746A (es)
CN (1) CN1635911A (es)
AP (1) AP2002002559A0 (es)
AR (1) AR034599A1 (es)
BG (1) BG108486A (es)
BR (1) BR0210505A (es)
CA (1) CA2455288A1 (es)
CR (1) CR7163A (es)
CZ (1) CZ20033341A3 (es)
EA (1) EA200301139A1 (es)
EC (1) ECSP034875A (es)
EE (1) EE200400024A (es)
GT (1) GT200200124A (es)
HN (1) HN2002000153A (es)
HU (1) HUP0400263A2 (es)
IL (1) IL158765A0 (es)
IS (1) IS7014A (es)
MA (1) MA27034A1 (es)
MX (1) MXPA04000014A (es)
NO (1) NO20035632L (es)
OA (1) OA12619A (es)
PA (1) PA8548601A1 (es)
PE (1) PE20030128A1 (es)
PL (1) PL368850A1 (es)
SK (1) SK15172003A3 (es)
SV (1) SV2003001103A (es)
TN (1) TNSN03139A1 (es)
UY (1) UY27344A1 (es)
WO (1) WO2003000295A2 (es)
ZA (1) ZA200308561B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512599A (en) * 1998-12-30 2003-10-31 Dexcel Ltd Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (ja) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 新規カプセル
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003074833A2 (en) * 2002-03-01 2003-09-12 Cesi Chemical, A Flotek Company Composition and process for well cleaning
US20040175341A1 (en) * 2003-03-04 2004-09-09 Manning Monna Marie Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
EP1603554A1 (en) * 2003-03-17 2005-12-14 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
ZA200508159B (en) * 2003-03-17 2007-03-28 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
US20040225018A1 (en) * 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CA2532931A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
JP2007507481A (ja) * 2003-09-30 2007-03-29 ファイザー・プロダクツ・インク Ｃｅｔｐ阻害薬及びその代謝産物
MXPA06003927A (es) * 2003-10-08 2008-02-07 Lilly Co Eli Compuestos y metodos para tratar dislipidemia.
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
ES2644450T3 (es) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. Nuevos derivados de bencilamina como inhibidores de CETP
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US7623458B2 (en) * 2005-09-30 2009-11-24 The Boeing Company System and method for providing integrated services across cryptographic boundaries in a network
ATE516016T1 (de) 2005-12-05 2011-07-15 Merck Sharp & Dohme Selbstemulgierende formulierungen von cetp- hemmern
MY148473A (en) * 2005-12-31 2013-04-30 Tasly Pharmaceutical Group Co Extracts of chenopodium ambrosioides l., the compositions comprising said extracts, the preparing process and application thereof
JP2009542677A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション トロンビン受容体拮抗薬の固形製剤
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
EP2373344B1 (en) * 2008-12-08 2016-03-30 F. Hoffmann-La Roche AG Combined drug administration
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
DK2442791T3 (da) 2009-06-16 2020-03-02 Pfizer Former til dosering af apixaban
KR20140037876A (ko) * 2011-05-20 2014-03-27 아벤티스 파마슈티칼스 인크. 펙소페나딘을 포함하는 약학적 조성물
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
WO2013059729A1 (en) 2011-10-21 2013-04-25 First Tech International Limited Tocotrienol compositions
CA2874593C (en) 2012-04-15 2017-05-09 Glenn S. Penny Surfactant formulations for foam flooding
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
CN104706586A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途
CN104706587A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种依托咪酯脂肪乳浓缩液、其制备方法及用途
CN104706689A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
US9505970B2 (en) 2014-05-14 2016-11-29 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10294757B2 (en) 2014-07-28 2019-05-21 Flotek Chemistry, Llc Methods and compositions related to gelled layers in oil and/or gas wells
RU2746548C2 (ru) 2014-11-04 2021-04-15 Иннофармакс, Инк. Пероральное введение неустойчивых или плохо всасывающихся лекарственных средств
CN104490775A (zh) * 2014-12-20 2015-04-08 长沙佰顺生物科技有限公司 一种安塞曲匹脂肪乳及其制备方法
CN104546710A (zh) * 2014-12-20 2015-04-29 长沙佰顺生物科技有限公司 一种安塞曲匹纳米乳及其制备方法
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
CN114209707A (zh) 2015-05-28 2022-03-22 瑞迪博士实验室有限公司 用于治疗疼痛的塞来昔布口服组合物
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
WO2019108971A1 (en) 2017-12-01 2019-06-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
MX2021006010A (es) * 2018-11-26 2021-09-21 Hepion Pharmaceuticals Inc Formulaciones farmaceuticas para analogos de ciclosporina.
CA3134550A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN110252395B (zh) 2019-07-01 2020-10-16 湖北远大生命科学与技术有限责任公司 一种用于制备高纯度牛磺酸的催化剂及其应用
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (fr) 2020-05-27 2024-03-15 Centre Nat Rech Scient Emulsions pour liberation controlee de medicaments
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
AU2517095A (en) 1994-05-19 1995-12-18 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
AU692255B2 (en) 1995-04-24 1998-06-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
EP0869810B1 (en) 1996-06-19 2004-10-06 Novartis AG Cyclosporin-containing soft capsule preparations
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
WO1999014204A1 (en) * 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
WO2000018723A1 (en) * 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
NZ512599A (en) 1998-12-30 2003-10-31 Dexcel Ltd Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6482862B1 (en) * 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
BR0210518A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de drogas e polìmeros neutros
JP2004534811A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
EP1469832B2 (en) * 2002-02-01 2016-10-26 Bend Research, Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
KR20040079967A (ko) * 2002-02-01 2004-09-16 화이자 프로덕츠 인크. 고체 약물 분산액을 함유하는 속방형 제형
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
HN2002000153A (es) 2002-11-05
BR0210505A (pt) 2004-05-18
AR034599A1 (es) 2004-03-03
NO20035632D0 (no) 2003-12-17
EE200400024A (et) 2004-06-15
IS7014A (is) 2003-10-31
US20060014788A1 (en) 2006-01-19
PA8548601A1 (es) 2003-09-05
ECSP034875A (es) 2004-01-28
CN1635911A (zh) 2005-07-06
ZA200308561B (en) 2004-11-17
TNSN03139A1 (fr) 2005-12-23
PL368850A1 (en) 2005-04-04
NO20035632L (no) 2004-02-18
KR20040015746A (ko) 2004-02-19
SK15172003A3 (en) 2004-11-03
CA2455288A1 (en) 2003-01-03
BG108486A (bg) 2005-03-31
JP2005500314A (ja) 2005-01-06
AP2002002559A0 (en) 2002-06-30
SV2003001103A (es) 2003-03-18
US20030022944A1 (en) 2003-01-30
WO2003000295A2 (en) 2003-01-03
EA200301139A1 (ru) 2004-12-30
GT200200124A (es) 2003-09-22
OA12619A (en) 2006-06-12
PE20030128A1 (es) 2003-02-28
EP1453544A2 (en) 2004-09-08
IL158765A0 (en) 2004-05-12
MXPA04000014A (es) 2004-05-21
UY27344A1 (es) 2003-01-31
WO2003000295A3 (en) 2004-05-27
US6962931B2 (en) 2005-11-08
HUP0400263A2 (hu) 2005-03-29
MA27034A1 (fr) 2004-12-20
CZ20033341A3 (cs) 2004-10-13

Similar Documents

Publication Publication Date Title
CR7163A (es) Formulaciones autoemulsionantes de inhibnidores de la proteina de transferencia de colesteril ester
ATE420619T1 (de) Ölige schäumbare aerosolzusammensetzung
CY1109135T1 (el) Φαρμακευτικο διαλυμα το οποιο περιλαμβανει ριτοναβιρη, εναν διαλυτη (μακριας αλυσιδας λιπαρο οξυ) και νερο
ATE398997T1 (de) Selbst-nanoemulgierende ölige formulierung zur verabreichung von schwer wasserlöslichen arzneimitteln
ATE365536T1 (de) Lösungsmittelsysteme für pharmazeutische mittel
DE60111422D1 (de) Erkennung von merkmalen in bildern
NO20030506L (no) Farmasöytiske sammensetninger av kolesterylesteroverföringsproteininhibitorer
EA200400765A1 (ru) Фармацевтические составы, содержащие соединения активного витамина d
CY1105167T1 (el) Συνθεσεις πepιεχουσες ενα κοσμετολογικα ενepγο οργανικο οξυ και ενα προϊον οσπριου
RS50422B (sr) Disperzioni preparati sa sadržajem inhibitora lipaza
DE60214537D1 (de) Entfernung von ölen aus säuren
MY127749A (en) Liquid formulation
SE0001494L (sv) Lipidkomposition och användning därav
NO20034139L (no) Faste oralt dispergerbare farmasöytiske formuleringer
DE60000223D1 (de) O/W-Emulsion enthaltende Fibern und ihre Verwendung in der Kosmetik
DE60123704T8 (de) Unterdrückung von Bildern und dazugehöriges Anzeigesystem
PL328916A1 (en) Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs
DK1372728T3 (da) Sammensætning omfattende en olie-i-vand-emulsion indeholdende konjugeret linolensyre
DOP2002000419A (es) Formulaciones autoemulsionantes de inhibidores de las protenia de transferencia de la colesteril ester.
SE0000730D0 (sv) Lipid carrier
ATE361757T1 (de) Stabile fumagillin-formulierung
DE60030487D1 (de) Verfahren und system von bildpunktdaten
WO2002053120A3 (de) Lichtschutzformulierungen mit einem gehalt an oberflächenaktiven saccharoseestern
PT1165091E (pt) Emulsoes farmaceuticas para inibidores de protease retroviral
TH43987A (th) อิมัลชันทางเภสัชกรรมสำหรับตัวยับยั้งรีโทรไวรอลโปรเทเอส

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)